Ismo Mattila

​Research Scientist,
Systems Medicine Research


Phone +45  30 91 33 43

Research area

I am an analytical chemist working in Systems Medicine group. I analyse biological samples using mass spectrometric methods. Currently I am using UHPLC-QTOF for analysing lipidomics samples. I analyse also untargeted global metabolomics samples using GC×GC-TOF instrument.

Current research


GALAXY has the ambition, by combining unique capabilities in European institutions, to perform integrated systems modelling of multi-omics data together with clinical data. To improve understanding of alcoholic liver fibrosis, and to develop diagnostic, prevention and treatment programs.
Read about the project


The portal vein transports metabolites produced by the human gut microbiota directly to the liver, and these may play a role in developing several liver diseases. The project will have access to many patients and will comprehensively screen their microbiota, liver and blood. The goal is to build models that describe the gut microbiome–portal vein–liver axis and to identify biomarkers for predicting, preventing and treating metabolic liver diseases.


The overall objective of INNODIA therefore is to advance in a decisive way how we predict, evaluate and prevent the onset and progression of type 1 diabetes (T1D), by creating novel tools, such as biomarkers, disease models and clinical trial paradigms.
Read about the project


The stated goal of RHAPSODY is to define a molecular taxonomy of type 2 diabetes mellitus (T2D) that will support patient segmentation, inform clinical trial design, and the establishment of regulatory paths for the adoption of novel strategies for diabetes prevention and treatment.
Read about the project

PROTON - PeRsOnalising Treatment Of diabetic Nephropathy

Responsible editor